医学
股骨头
不利影响
可视模拟标度
哈里斯髋关节评分
骨关节炎
外科
骨科手术
放射性武器
臀部疼痛
内科学
关节置换术
病理
替代医学
作者
Yutaka Kuroda,Toshiko Ito-Ihara,Hiroyasu Abe,Manabu Nankaku,Yaichiro Okuzu,Toshiyuki Kawai,Koji Goto,Shinya Matsuda
出处
期刊:Regenerative Medicine
[Future Medicine]
日期:2020-11-01
卷期号:15 (11): 2261-2271
被引量:5
标识
DOI:10.2217/rme-2020-0148
摘要
Aim: To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Methods: Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel. Radiological changes and the prevalidated Harris hip score (HHS), visual analogue scale for pain and University of California, Los Angeles activity-rating scale scoring systems were evaluated. Results: The 5-year comparison in type C2 showed higher joint preservation in the rhFGF-2 group (71.4%) than in the natural course group (15.4%). Two of three clinical scores (Harris hip score and visual analogue scale for pain) improved significantly. Postoperative MRI demonstrated significant reduction in ONFH size. There were no adverse events. Conclusion: rhFGF-2 treatment for ONFH appears to be safe and effective and may have the potential to prevent disease progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI